News
ATTO
15.19
-0.52%
-0.08
Weekly Report: what happened at ATTO last week (1019-1023)?
Weekly Report · 5d ago
Attovia Therapeutics Becomes Oversold (ATTO)
NASDAQ · 10/23 20:35
Weekly Report: what happened at ATTO last week (1012-1016)?
Weekly Report · 10/19 10:34
Attovia Therapeutics: Buy Rating Reaffirmed on Pipeline Momentum and Upcoming Catalysts, Price Target Unchanged at $30
TipRanks · 10/14 10:36
Weekly Report: what happened at ATTO last week (1005-1009)?
Weekly Report · 10/12 10:41
Weekly Report: what happened at ATTO last week (0928-1002)?
Weekly Report · 10/05 10:40
Attovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress And FCD 2026
Benzinga · 09/28 20:06
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
Barchart · 09/28 15:05
Weekly Report: what happened at ATTO last week (0921-0925)?
Weekly Report · 09/28 10:34
Weekly Report: what happened at ATTO last week (0914-0918)?
Weekly Report · 09/21 10:34
Weekly Report: what happened at ATTO last week (0907-0911)?
Weekly Report · 09/14 10:40
Weekly Report: what happened at ATTO last week (0831-0904)?
Weekly Report · 09/07 10:32
Primary Markets Group August IPO Update
Seeking Alpha · 09/05 06:30
5 Biotech And Medical Device Stocks In Focus: Pro-Dex, Modular Medical, ENvue Medical & More
NASDAQ · 09/04 18:36
Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday
Benzinga · 09/04 15:26
Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN)
TipRanks · 09/04 10:30
Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRC
NASDAQ · 09/04 09:15
Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27
NASDAQ · 09/03 16:47
Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway
TipRanks · 09/03 15:55
Morgan Stanley Gives a Buy Rating to Attovia Therapeutics, Inc. (ATTO)
TipRanks · 09/03 13:05
More
Webull provides a variety of real-time ATTO stock news. You can receive the latest news about Attovia Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATTO
Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. It is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.